<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Non-alcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease is now recognized as the hepatic component of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Non-alcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease is a spectrum of fat-associated liver conditions that can result in <z:e sem="disease" ids="C0745744" disease_type="Disease or Syndrome" abbrv="">end-stage liver disease</z:e> and the need for liver transplantation </plain></SENT>
<SENT sid="2" pm="."><plain>Simple <z:hpo ids='HP_0001397'>steatosis</z:hpo>, or <z:hpo ids='HP_0001397'>fatty liver</z:hpo>, occurs early in non-alcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease and may progress to <z:e sem="disease" ids="C0400966" disease_type="Disease or Syndrome" abbrv="">non-alcoholic steatohepatitis</z:e>, <z:mp ids='MP_0003045'>fibrosis</z:mp> and <z:hpo ids='HP_0001394'>cirrhosis</z:hpo> with increased risk of <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Prevalence estimates for non-alcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease range from 17 to 33% in the general populations and it has been estimated that non-alcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease exists in up to 70% of people with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Non-alcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease increases risk of Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In people with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, non-alcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease is the most frequent cause (âˆ¼80%) of <z:hpo ids='HP_0001397'>fatty liver</z:hpo> diagnosed by ultrasound </plain></SENT>
<SENT sid="6" pm="."><plain>As non-alcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease is strongly associated with <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, the presence of non-alcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease with <z:mp ids='MP_0002055'>diabetes</z:mp> often contributes to poor glycaemic control </plain></SENT>
<SENT sid="7" pm="."><plain>Consequently, strategies that decrease liver fat and improve whole-body insulin sensitivity may both contribute to prevention of Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and to better glycaemic control in people who already have developed <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>This review summarizes the Dorothy Hodgkin lecture given by the author at the 2012 <z:mp ids='MP_0002055'>Diabetes</z:mp> UK annual scientific conference, proposing that fatty acid fluxes through the liver are crucial for the pathogenesis of non-alcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease and for increasing <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
</text></document>